{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:43:19Z","timestamp":1780555399463,"version":"3.54.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40273-024-01380-0","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T15:04:16Z","timestamp":1716303856000},"page":"811-822","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cost Effectiveness of Fremanezumab in Episodic and Chronic Migraine Patients from a Japanese Healthcare Perspective"],"prefix":"10.1007","volume":"42","author":[{"given":"Takao","family":"Takeshima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3151-8092","authenticated-orcid":false,"given":"Xinyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5027-6289","authenticated-orcid":false,"given":"Kentaro","family":"Yamato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0286-8765","authenticated-orcid":false,"given":"Yoshitsugu","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3139-3824","authenticated-orcid":false,"given":"Yilong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8658-5510","authenticated-orcid":false,"given":"Craig","family":"Bennison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5248-1676","authenticated-orcid":false,"given":"Martijn J. H. G.","family":"Simons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"issue":"1","key":"1380_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11916-011-0233-z","volume":"16","author":"Z Katsarava","year":"2012","unstructured":"Katsarava Z, Buse DC, Manack AN, et al. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16(1):86\u201392.","journal-title":"Curr Pain Headache Rep"},{"key":"1380_CR2","unstructured":"Japanese Society of Neurology and the Japanese Headache Society. Clinical practice guideline for chronic headache. https:\/\/www.neurology-jp.org\/guidelinem\/ch\/index.html. Accessed 22 Apr 22 2020. 2013."},{"issue":"1","key":"1380_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s10194-022-01402-2","volume":"23","author":"LJ Stovner","year":"2022","unstructured":"Stovner LJ, Hagen K, Linde M, et al. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain. 2022;23(1):34.","journal-title":"J Headache Pain"},{"issue":"1","key":"1380_CR4","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s10194-022-01471-3","volume":"23","author":"C Rosignoli","year":"2022","unstructured":"Rosignoli C, Ornello R, Onofri A, et al. Applying a biopsychosocial model to migraine: rationale and clinical implications. J Headache Pain. 2022;23(1):100.","journal-title":"J Headache Pain"},{"issue":"10","key":"1380_CR5","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1111\/j.1526-4610.2012.02223.x","volume":"52","author":"DC Buse","year":"2012","unstructured":"Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52(10):1456\u201370.","journal-title":"Headache"},{"key":"1380_CR6","unstructured":"WHO. Headache disorders. 2016. http:\/\/www.who.int\/mediacentre\/factsheets\/fs277\/en. 2017. Accessed 20 Nov 2023."},{"key":"1380_CR7","doi-asserted-by":"crossref","unstructured":"Vos T, Abajobir AA, Abbafati C, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390(10100):1211\u201359.","DOI":"10.1016\/S0140-6736(17)32154-2"},{"issue":"3","key":"1380_CR8","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s41669-018-0105-0","volume":"3","author":"JK Porter","year":"2019","unstructured":"Porter JK, Di Tanna GL, Lipton RB, et al. Costs of acute headache medication use and productivity losses among patients with migraine: insights from three randomized controlled trials. Pharmacoecon Open. 2019;3(3):411\u20137.","journal-title":"Pharmacoecon Open"},{"issue":"4","key":"1380_CR9","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1526-4610.2009.01369.x","volume":"49","author":"J Munakata","year":"2009","unstructured":"Munakata J, Hazard E, Serrano D, et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2009;49(4):498\u2013508.","journal-title":"Headache"},{"issue":"1","key":"1380_CR10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s10194-023-01666-2","volume":"24","author":"P Martelletti","year":"2023","unstructured":"Martelletti P, Leonardi M, Ashina M, et al. Rethinking headache as a global public health case model for reaching the SDG 3 HEALTH by 2030. J Headache Pain. 2023;24(1):140.","journal-title":"J Headache Pain"},{"issue":"1","key":"1380_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s10194-023-01699-7","volume":"24","author":"B Raffaelli","year":"2023","unstructured":"Raffaelli B, Rubio-Beltr\u00e1n E, Cho SJ, et al. Health equity, care access and quality in headache\u2014part 2. J Headache Pain. 2023;24(1):167.","journal-title":"J Headache Pain"},{"issue":"1","key":"1380_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s10194-024-01712-7","volume":"25","author":"C Tana","year":"2024","unstructured":"Tana C, Raffaelli B, Souza MNP, et al. Health equity, care access and quality in headache\u2014part 1. J Headache Pain. 2024;25(1):12.","journal-title":"J Headache Pain"},{"issue":"1","key":"1380_CR13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10194-019-1012-1","volume":"20","author":"K Ueda","year":"2019","unstructured":"Ueda K, Ye W, Lombard L, et al. Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme. J Headache Pain. 2019;20(1):68.","journal-title":"J Headache Pain"},{"issue":"1","key":"1380_CR14","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12883-020-01848-4","volume":"20","author":"K Hirata","year":"2020","unstructured":"Hirata K, Ueda K, Ye W, et al. Factors associated with insufficient response to acute treatment of migraine in Japan: analysis of real-world data from the Adelphi Migraine Disease Specific Programme. BMC Neurol. 2020;20(1):274.","journal-title":"BMC Neurol"},{"issue":"Suppl 1","key":"1380_CR15","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.4274\/npa.y7199","volume":"50","author":"AE G\u00fcrsoy","year":"2013","unstructured":"G\u00fcrsoy AE, Erta\u015f M. Prophylactic treatment of migraine. Noro Psikiyatr Ars. 2013;50(Suppl 1):S30-s35.","journal-title":"Noro Psikiyatr Ars"},{"issue":"8","key":"1380_CR16","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1080\/14737175.2019.1621749","volume":"19","author":"A Negro","year":"2019","unstructured":"Negro A, Martelletti P. Patient selection for migraine preventive treatment with anti-CGRP(r) monoclonal antibodies. Expert Rev Neurother. 2019;19(8):769\u201376.","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"1380_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/14728214.2023.2207819","volume":"28","author":"M Silvestro","year":"2023","unstructured":"Silvestro M, Orologio I, Siciliano M, et al. Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials. Expert Opin Emerg Drugs. 2023;28(2):79\u201396.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"4 Headache","key":"1380_CR18","first-page":"973","volume":"21","author":"SD Silberstein","year":"2015","unstructured":"Silberstein SD. Preventive Migraine Treatment. Continuum (Minneap Minn). 2015;21(4 Headache):973\u201389.","journal-title":"Continuum (Minneap Minn)"},{"issue":"7","key":"1380_CR19","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/head.14178","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Kim BK, et al. Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache. 2021;61(7):1102\u201311.","journal-title":"Headache"},{"issue":"7","key":"1380_CR20","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/head.14169","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Kim BK, et al. Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache. 2021;61(7):1092\u2013101.","journal-title":"Headache"},{"key":"1380_CR21","unstructured":"National institute for Health and Care Excellence. Fremanezumab for preventing migraine. 2020."},{"key":"1380_CR22","unstructured":"ICER. Calcitonin Gene-Related Peptide (CGRP) Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine: Effectiveness and Value - Evidence Report. 2018."},{"issue":"1","key":"1380_CR23","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s10194-022-01492-y","volume":"23","author":"S Khanal","year":"2022","unstructured":"Khanal S, Underwood M, Naghdi S, et al. A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine. J Headache Pain. 2022;23(1):122.","journal-title":"J Headache Pain"},{"key":"1380_CR24","unstructured":"Core-2-Health. Full Scale Introduction of Cost-Effectiveness Evaluations in Japan - Overview (2\/20\/2019). Available at: https:\/\/c2h.niph.go.jp\/tools\/system\/overview_en.pdf. 2019. Accessed 18 Dec 2023."},{"key":"1380_CR25","doi-asserted-by":"crossref","unstructured":"Wang X, Yamato K, Kojima Y, et al. Modeling monthly migraine-day distributions using longitudinal regression models and linking quality of life to inform cost-effectiveness analysis: a case study of fremanezumab in Japanese-Korean Migraine Patients. Pharmacoeconomics 2023;41(10):1263\u201374.","DOI":"10.1007\/s40273-023-01288-1"},{"issue":"12","key":"1380_CR26","first-page":"1355","volume":"44","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Ning X, et al. Long-term safety and tolerability of fremanezumab for migraine preventive treatment in japanese outpatients: a multicenter, randomized. Open-Label Study Drug Saf. 2021;44(12):1355\u201364.","journal-title":"Open-Label Study. Drug Saf"},{"issue":"5","key":"1380_CR27","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/j.1468-2982.2008.01555.x","volume":"28","author":"S Silberstein","year":"2008","unstructured":"Silberstein S, Tfelt-Hansen P, Dodick DW, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia. 2008;28(5):484\u201395.","journal-title":"Cephalalgia"},{"issue":"1","key":"1380_CR28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/0333102411417901","volume":"32","author":"P Tfelt-Hansen","year":"2012","unstructured":"Tfelt-Hansen P, Pascual J, Ramadan N, et al. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia. 2012;32(1):6\u201338.","journal-title":"Cephalalgia"},{"key":"1380_CR29","doi-asserted-by":"crossref","unstructured":"James SL, Abate D, Abate HK, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789\u2013858.","DOI":"10.1016\/S0140-6736(18)32279-7"},{"key":"1380_CR30","unstructured":"Mhlw.go.jp. Abridged Life Tables for Japan 2019. [online] Available at: https:\/\/www.mhlw.go.jp\/english\/database\/db-hw\/lifetb19\/index.html. 2021."},{"key":"1380_CR31","unstructured":"Core-2-Health. Guideline for Preparing Cost-Effectiveness Evaluation to the Central Social Insurance Medical Council. [online] Available at: https:\/\/c2h.niph.go.jp\/tools\/guideline\/guideline_en.pdf. 2022; Version 3.0. Accessed 28 Mar 2024."},{"issue":"1","key":"1380_CR32","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s10194-020-01180-9","volume":"21","author":"S Kikui","year":"2020","unstructured":"Kikui S, Chen Y, Todaka H, et al. Burden of migraine among Japanese patients: a cross-sectional National Health and Wellness Survey. J Headache Pain. 2020;21(1):110.","journal-title":"J Headache Pain"},{"key":"1380_CR33","unstructured":"JMDC. Database. https:\/\/www.jmdc.co.jp\/bigdata\/. 2021. Accessed 28 Sep 2023."},{"issue":"1","key":"1380_CR34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40120-021-00305-9","volume":"11","author":"Y Matsumori","year":"2022","unstructured":"Matsumori Y, Ueda K, Komori M, et al. Burden of migraine in Japan: results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) Study. Neurol Ther. 2022;11(1):205\u201322.","journal-title":"Neurol Ther"},{"key":"1380_CR35","unstructured":"Ministry of Health Labour and Welfare. Drug price fremanezumab https:\/\/www.mhlw.go.jp\/content\/12404000\/001068211.pdf. 2022. Accessed 31 Oct 2023."},{"key":"1380_CR36","unstructured":"Ministry of Health Labour and Welfare. Overview of the 2020 Wage Structure Basic Statistical Survey. Available at: https:\/\/www.mhlw.go.jp\/toukei\/itiran\/roudou\/chingin\/kouzou\/z2022\/dl\/13.pdf. 2022. Accessed 28 Mar 2024."},{"issue":"4","key":"1380_CR37","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","volume":"34","author":"P Vemer","year":"2016","unstructured":"Vemer P, Corro Ramos I, van Voorn GA, et al. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34(4):349\u201361.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1380_CR38","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s10194-021-01358-9","volume":"22","author":"P McAllister","year":"2021","unstructured":"McAllister P, Lamerato L, Krasenbaum LJ, et al. Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States. J Headache Pain. 2021;22(1):156.","journal-title":"J Headache Pain"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01380-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-024-01380-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01380-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T05:04:46Z","timestamp":1718427886000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-024-01380-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1380"],"URL":"https:\/\/doi.org\/10.1007\/s40273-024-01380-0","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,21]]},"assertion":[{"value":"7 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by Otsuka Pharmaceuticals Co., Ltd. The funding source had a supervising role in conducting the study and in preparing the manuscript. The open access fee was paid by Otsuka Pharmaceuticals Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Takao Takeshima reports consulting fees or honorarium by Otsuka, Amgen, Eli-Lilly, Daiichi Sankyo, Shionogi, Bioheaven, and Lundbeck and being an advisor of Hedgehog MedTech and Sawai. Fumihiko Sakai reports consulting fees or honorarium by Otsuka, Amgen, Eli-Lilly, and Daiichi Sankyo. Xinyu Wang was employed by Otsuka Pharmaceutical Co., Ltd. during the conduct of the study and reports no conflicts of interest. Kentaro Yamato, Yoshitsugu Kojima, and Yilong Zhang are employed by Otsuka Pharmaceutical Co., Ltd. and report no conflicts of interest. Otsuka Pharmaceutical Co., Ltd. launched fremanezumab in Japan. Craig Bennison and Martijn Simons are employed by OPEN Health and report consulting fees from Otsuka. OPEN Health is a consultancy firm that was contracted by Otsuka to conduct the study and write the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The model developed during the current study is not publicly available due to confidentiality. The input data supporting the model are from previously reported publications and reports, which have been cited. No new data were generated or analyzed during the current study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data analyses were performed in R statistical software and the model was created and analyzed in Excel.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization and design: XW, KY, YK, YZ, CB, MS. Data acquisition: XW, YZ. Methodology: TT, FS, XW, KY, YK, YZ, CB, MS. Formal analysis and interpretation of the data: XW, KY, YK, YZ, CB, MS. Validation: TT, FS, XW, KY, YK, YZ, CB, MS. Writing original draft: XW, YZ, CB, MS. Writing review and editing: TT, FS, XW, KY, YK, YZ, CB, MS. Critical revision of the article for important intellectual content: TT, FS, XW, KY, YK, YZ, CB, MS.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}